Pharmacokinetic Study of Raltegravir in HIV-Infected Patients With End-Stage Liver Disease: The LIVERAL-ANRS 148 Study

Characterization of Binding of Raltegravir to Plasma Proteins

(2013) Caroline Barau et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C)

(2013) B. Hernandez-Novoa et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C

(2011) J. Macias et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects

(2011) D. Cattaneo et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Clinical Pharmacology Profile of Raltegravir, an HIV-1 Integrase Strand Transfer Inhibitor

(2011) Diana M. Brainard et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Limited Sampling Strategies for the Estimation of Raltegravir Daily Exposure in HIV-Infected Patients

(2011) Dario Cattaneo et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients

(2010) Aurélie Barrail-Tran et al.   AIDS

Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials

(2010) Roy T. Steigbigel et al.   CLINICAL INFECTIOUS DISEASES

Safety and Efficacy of Raltegravir in HIV-Infected Transplant Patients Cotreated with Immunosuppressive Drugs

(2009) L. Tricot et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics

(2009) M. Iwamoto et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Switch from Enfuvirtide to Raltegravir in Virologically Suppressed Multidrug‐Resistant HIV‐1–Infected Patients: A Randomized Open‐Label Trial

(2009) Nathalie De Castro et al.   CLINICAL INFECTIOUS DISEASES

Effects of Omeprazole on Plasma Levels of Raltegravir

(2009) Marian Iwamoto et al.   CLINICAL INFECTIOUS DISEASES

High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment‐Experienced Patients Infected with Multidrug‐Resistant HIV: Results of the ANRS 139 TRIO Trial

(2009) Y. Yazdanpanah et al.   CLINICAL INFECTIOUS DISEASES

A LC–tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine

(2009) A. Fayet et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

(2009) Jeffrey L Lennox et al.   LANCET

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

(2008) Roger K. Verbeeck   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY